Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Aye, Ralph
J1414, NCT02259621: Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC In adults with untreated, surgically resectable early (stage I, II, or IIIA) NSCLC May 2018 - May 2018: In adults with untreated, surgically resectable early (stage I, II, or IIIA) NSCLC ASCO 2016 May 2016 - May 2016: ASCO 2016	Active, not recruiting	2	39	Canada, US	Nivolumab, BMS-936558 or MDX1106, Carboplatin, Paraplatin, Paclitaxel, Taxol, Onxal, Ipilimumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb	Non-Small Cell Lung Cancer	10/22	10/27
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer	Recruiting	N/A	1050	Europe, US	Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay	Razor Genomics, Encore Clinical	Non-Small Cell Lung Cancer	05/27	05/27